Pregnant women taking dolutegravir were significantly more likely to have a fully suppressed viral load at the time of delivery compared to women taking atazanavir/ritonavir or raltegravir, researchers in the United States report in the New England Journal of Medicine.
The researchers say that their findings support the use of dolutegravir in preference to atazanavir/ritonavir or raltegravir during pregnancy, with darunavir/ritonavir as an alternative where dolutegravir use is not feasible.
Several clinical trials have shown that dolutegravir treatment leads to superior viral suppression at the time of delivery – which minimises the risk of vertical HIV transmission – compared to efavirenz or to atazanavir/ritonavir. However, current guidelines for the use of antiretrovirals during pregnancy vary, partly due to the date they were last revised.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.